Profound Medical (TSX:PRN) Total Liabilities: C$17.65 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:PRN Profound Medical Corp TSX:PRN
71 GF Score
Price C$9.32
GF Value C$14.73
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Profound Medical Total Liabilities?

Profound Medical TSX:PRN +2.42% 71 Total Liabilities is C$17.65 Mil as of Jun. 2026. GuruFocus rates TSX:PRN with a GF Score™ of 71/100 and a GF Value™ of C$14.73 (Possible Value Trap). The stock has 1 warning sign investors should review.

Profound Medical's Total Liabilities for the quarter that ended in Jun. 2026 was C$17.65 Mil.

Profound Medical's quarterly Total Liabilities increased from Dec. 2025 (C$15.23 Mil) to Mar. 2026 (C$19.25 Mil) but then declined from Mar. 2026 (C$19.25 Mil) to Jun. 2026 (C$17.65 Mil).

Profound Medical's annual Total Liabilities declined from Dec. 2023 (C$17.08 Mil) to Dec. 2024 (C$13.98 Mil) but then increased from Dec. 2024 (C$13.98 Mil) to Dec. 2025 (C$15.23 Mil).

Profound Medical Total Liabilities Historical Data

* Premium members only.

The historical data trend for Profound Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profound Medical Total Liabilities Chart

Profound Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.88 16.87 17.08 13.98 15.23

Profound Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.23 14.06 15.23 19.25 17.65
TSX:PRN
71GF Score
Profound Medical Corp TSX:PRN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Profound Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Profound Medical's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.38+(6.206+0.11
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.535+0+0)
=15.23

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=106.877-91.646
=15.23

Profound Medical's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.789+(3.865+0.13
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.867+0+0)
=17.65

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=87.551-69.901
=17.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of C$17.65 Mil mean?
Profound Medical (TSX:PRN) has a Total Liabilities of C$17.65 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Profound Medical and its competitors.
Is Profound Medical's Total Liabilities too high?
Profound Medical's current Total Liabilities is C$17.65 Mil. Overall, Profound Medical has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Total Liabilities compare to ABT and SYK?
Profound Medical's Total Liabilities of C$17.65 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Profound Medical and its competitors. Profound Medical's current Total Liabilities is C$17.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$14.73, compared to a current price of C$9.32 — trading 36.7% below its estimated fair value. The current Total Liabilities is C$17.65 Mil. Profound Medical's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current Total Liabilities is C$17.65 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Profound Medical (TSX:PRN) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of C$9.32 is trading 36.7% below its estimated GF Value™ of C$14.73. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for TSX:PRN:

  • Total Liabilities: C$17.65 Mil
  • GF Value™: C$14.73 vs. price of C$9.32 (36.7% below fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Other Exchanges PROF:USA
Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
71GF Score

Get the complete analysis for TSX:PRN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.32
Price
C$14.73
GF Value